CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

Beacon Health System, Inc. and Affiliated Corporations Years Ended December 31, 2023 and 2022 With Reports of Independent Auditors

Ernst & Young LLP



Consolidated Financial Statements and Supplementary Information

Years Ended December 31, 2023 and 2022

Contents

Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	5
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8
Supplementary Information	
•	4.77
Report of Independent Auditors on Supplementary Information	4/
Details of Consolidated Balance Sheet, December 31, 2023	
Details of Consolidated Balance Sheet, December 31, 2022	50
Details of Consolidated Statement of Operations and Changes in	
Net Assets, Year Ended December 31, 2023	52
Details of Consolidated Statement of Operations and Changes in	
Net Assets, Year Ended December 31, 2022.	54



Ernst & Young LLP 155 North Wacker Drive Chicago, IL 60606-1787 Tel: +1 312 879 2000 Fax: +1 312 879 4000 ey.com

Report of Independent Auditors

The Board of Directors Beacon Health System, Inc. and Affiliated Corporations

Opinion

We have audited the consolidated financial statements of Beacon Health System, Inc. and Affiliated Corporations (the Corporation), which comprise the consolidated balance sheets as of December 31, 2023 and 2022, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Corporation at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for one year after the date that the financial statements are issued.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks.
 Such procedures include examining, on a test basis, evidence regarding the amounts and
 disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing
 an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such
 opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal-control-related matters that we identified during the audit.

Ernst + Young LLP

March 8, 2024

Consolidated Balance Sheets

(In Thousands)

	December 31			31	
	2023			2022	
Assets					
Current assets:					
Cash and cash equivalents	\$	115,964	\$	70,805	
Short-term investments		84,949		32,935	
Patient accounts receivable		232,093		217,013	
Due from third-party payors		49,704		34,409	
Other receivables		15,946		37,603	
Other current assets		905		1,060	
Inventories		36,315		31,329	
Prepaid expenses		21,268		22,502	
Total current assets		557,144		447,656	
Assets limited as to use:					
Internally designated investments		832,892		800,871	
Restricted cash		6,778		5,708	
Externally designated investments – insurance trust		2,884		2,760	
Board-designated endowment		31,624		29,406	
Endowment and temporarily restricted investments		11,220		10,152	
• •		885,398		848,897	
Property and equipment:					
Land		65,736		68,572	
Buildings and improvements		973,765		928,917	
Furniture and equipment		548,710		523,444	
Construction-in-progress		60,737		54,537	
		1,648,948		1,575,470	
Less allowances for depreciation and amortization		904,417		845,442	
		744,531		730,028	
Deferred charges and other assets		79,446		83,553	
Total assets	\$	2,266,519	\$	2,110,134	

3 2401-4414437

Consolidated Balance Sheets (continued) (In Thousands)

	December 31			31
	2023			2022
Liabilities and net assets				
Current liabilities:				
Accounts payable	\$	64,287	\$	73,905
Accrued salaries and benefits		59,640		54,230
Accrued expenses		4,327		4,966
Other current liabilities		933		1,076
Due to third-party payors		2,121		7,279
Current maturities of long-term debt		13,873		16,533
Total current liabilities		145,181		157,989
Noncurrent liabilities:				
Long-term debt, less current maturities		344,734		288,829
Other liabilities		13,801		14,254
Interest rate and basis swaps		6,078		11,031
		364,613		314,114
Total liabilities		509,794		472,103
Net assets:				
Without donor restrictions		1,737,471		1,620,864
With donor restrictions		19,254		17,167
Total net assets		1,756,725		1,638,031

Total liabilities and net assets	\$ 2266 519	\$ 2,110,134
Total habilities and net assets	\$ 2,200,319	\$ 2,110,134

See accompanying notes.

Consolidated Statements of Operations and Changes in Net Assets (In Thousands)

	Year Ended December 31		
	2023	2022	
Unrestricted revenue, gains, and other support	•	_	
Patient service revenue	\$ 1,290,004	\$ 1,205,384	
Other revenue	72,270	88,619	
Net assets released from restrictions used for operations	1,197	1,911	
	1,363,471	1,295,914	
Expenses			
Salaries and wages	620,270	639,985	
Employee benefits	140,327	122,874	
Supplies and other	336,087	329,135	
Professional fees and purchased services	155,288	148,003	
Depreciation and amortization	63,182	63,345	
Interest	7,761	6,867	
	1,322,915	1,310,209	
Income (loss) from operations	40,556	(14,295)	
Nonoperating income (expenses)			
Investment income (losses), net	70,870	(92,938)	
Unrealized gains on swap transactions, net	4,953	5,853	
Gain on lease termination		39	
Revenue and gains in excess of (less than) expenses	116,379	(101,341)	

2401-4414437 5

Consolidated Statements of Operations and Changes in Net Assets (continued) (In Thousands)

	Year Ended December 31			cember 31
		2023		2022
Net assets without donor restrictions				
Revenue and gains in excess of (less than) expenses	\$	116,379	\$	(101,341)
Net assets released from restrictions used for				
capital purposes		228		1,499
Net assets released from restriction by donor and other		_		15
Increase (decrease) in net assets without donor restrictions		116,607		(99,827)
Net assets with donor restrictions				
Purpose-restricted contributions		2,438		3,705
Investment income (losses)		1,074		(1,509)
Net assets released from restrictions used for				
operating and capital purposes		(1,425)		(3,286)
Increase (decrease) in net assets with donor restrictions		2,087		(1,090)
Change in net assets		118,694		(100,917)
Net assets at beginning of year		1,638,031		1,738,948
Net assets at end of year	\$	1,756,725	\$	1,638,031

See accompanying notes.

Consolidated Statements of Cash Flows

(In Thousands)

	Year Ended Dece 2023	mber 31 2022
Operating activities		
Change in net assets	\$ 118,694 \$	(100,917)
Adjustments to reconcile change in net assets to net		
cash provided by operating activities:		
Depreciation and amortization	63,182	63,345
Unrealized gains on swap transactions, net	(4,953)	(5,853)
Gain on lease termination	_	(39)
Unrealized gains (losses) on investments	(42,660)	112,416
Restricted contributions and investment income	(3,512)	(2,196)
Changes in operating assets and liabilities:		
Patient accounts receivable	(15,080)	19,697
Other receivables, inventories, and prepaid expenses	18,060	(20,958)
Other assets	4,143	(9,694)
Investments – trading	7,229	61,484
Accounts payable, accrued salaries and benefits, and accrued expenses	(4,990)	(15,882)
Due to/from third-party payors, net	(20,453)	(71,958)
Other long-term liabilities	(630)	(3,719)
Net cash provided by operating activities	119,030	25,726
Investing activities		
Additions to property and equipment, net	(76,348)	(87,910)
Net cash used in investing activities	(76,348)	(87,910)
Financing activities		
Principal payments on long-term debt and other debt obligations	(17,653)	(11,346)
Proceeds from long-term debt	70,020	32,220
Payment of bond issue costs	(318)	_
Restricted contributions and investment income	 3,512	2,196
Net cash provided by financing activities	55,561	23,070
Increase (decrease) in cash and cash equivalents and restricted cash	98,243	(39,114)
Cash and cash equivalents and restricted cash at beginning of year	 109,448	148,562
Cash and cash equivalents and restricted cash at end of year	\$ 207,691 \$	109,448
Reconciliation of cash and cash equivalents and restricted cash to the		
consolidated balance sheets:		
Cash and cash equivalents	\$ 115,964 \$	70,805
Short-term investments	84,949	32,935
Restricted cash included in assets limited as to use	 6,778	5,708
	\$ 207,691 \$	109,448
Supplemental disclosure of cash flow information		
Interest paid	\$ 7,952 \$	6,703

See accompanying notes.

Notes to Consolidated Financial Statements (Dollars in Thousands)

December 31, 2023

1. Organization and Basis of Consolidation

The accompanying consolidated financial statements represent the accounts of Beacon Health System, Inc. (the Corporation) and its various affiliated corporations under the control of the Corporation (collectively, BHS). The Corporation is an Indiana not-for-profit corporation exempt from federal income tax under Internal Revenue Code (the Code) Section 501(a) as an organization described in Section 501(c)(3) and a public charity, as described in Section 509(a)(3). The Corporation is the sole corporate member of the following entities:

- Elkhart General Hospital, Inc. (EGH)
- Memorial Hospital of South Bend, Inc. (MHSB)
- Beacon Health Foundation, Inc. (BHF)
- Beacon Medical Group, Inc. (BMG)
- Beacon Health Ventures, Inc. (BHV)
- Beacon Occupational Health, LLC (BOH)
- CHA ACO, LLC (CHA ACO)
- Beacon Health, LLC (BH)
- Community Hospital of Bremen, Inc. (CHB)
- BPL Acquisitions, LLC
- Beacon Specialty Surgery, LLC (BSS)
- Three Rivers Health System, Inc. (TRH)

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

1. Organization and Basis of Consolidation (continued)

EGH, MHSB, CHB, BMG, TRH, and BHF are also exempt from federal income tax under Section 501(a) of the Code as organizations described in Section 501(c)(3) and as public charities described in Sections 509(a)(1) and 509(a)(2). BHV and BOH are Indiana for-profit corporations. EGH is a 365-licensed-bed (254 available) acute care community hospital located in Elkhart, Indiana. MHSB is a 657-licensed-bed (409 available) acute care trauma center located in South Bend, Indiana. CHB is a 24-bed critical access hospital located in Bremen, Indiana. TRH is a 60-bed short-term acute-care facility located in Three Rivers, Michigan. EGH, MHSB, CHB, and TRH (collectively, the Hospitals) provide inpatient, outpatient, and 24-hour emergency care services for residents of Three Rivers, Michigan, and Elkhart; South Bend; and Bremen, Indiana, and the surrounding communities.

TRH includes Integrated Health Systems (IHS) and Three Rivers Health Foundation (TRHF). IHS is a for-profit company whose purpose is to employ physicians who work at TRH as contracted employees. TRHF is a nonprofit organization whose purpose is to fund projects of TRH. As of December 31, 2022, IHS and TRHF were dissolved. All TRHF funds were distributed and future fundraising activity will run through BHF.

BHF is organized primarily to promote and encourage philanthropic activities for the support of the Corporation and its affiliates.

BHV manages the taxable operations of the Corporation, including home care and other non-acute health care services.

BOH primarily promotes population health management.

CHA ACO coordinates high-quality care for Medicare beneficiaries participating in the Medicare Shared Savings Programs.

BMG operates the physician enterprise of the Corporation.

BH improves and expands delivery and quality of health care services for the Corporation.

BPL Acquisitions, LLC is a real estate holding company established to purchase land.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

1. Organization and Basis of Consolidation (continued)

BSS, previously a joint venture that is now fully owned by BMG, is an outpatient surgery center specializing in neurologic, spine, and pain control procedures.

All significant intercompany accounts and transactions have been eliminated in consolidation.

The Corporation owns a less-than-majority ownership or controlling interest in the following:

- 50% interest in Community Health Alliance LLC, an Indiana physician hospital organization
- 25% interest in Magnetic Resonance Imaging, LLC, an imaging and radiology center
- 40% interest in Elkhart Health, Fitness & Aquatics, Inc., a health fitness and aquatics center
- 10% interest in Alick's Home Medical Equipment, Inc., a home medical equipment provider
- 54% interest in South Bend Specialty Surgery Center, LLC, an outpatient surgery center. Although the Corporation owns a majority financial interest in this entity, it does not possess a controlling interest in the entity, and therefore does not consolidate the LLC.
- 50% interest in Franciscan Beacon Health, an acute care hospital located in LaPorte, Indiana
- 51% interest in ASC Ventures LLC, an ambulatory surgery center located in Granger, Indiana
- 20% interest in Northern Indiana Ambulatory Surgery Center, LLC d/b/a/ Riverpointe Surgery Center, an ambulatory surgery center located in Elkhart, Indiana

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

1. Organization and Basis of Consolidation (continued)

Aggregate financial information relating to these investments is as follows:

	 2023	2022
Assets	\$ 133,470 \$	119,265
Liabilities	49,062	29,226
Net income	4,694	1,339

At December 31, 2023 and 2022, the Corporation has \$59,782 and \$59,367, respectively, related to these equity method investments recorded in deferred charges and other assets on the consolidated balance sheets. During 2023, the Corporation sold its interests in LaPorte Medical Group Surgery Center, LLP, and Michiana Information Health Network, Inc. The loss was not material. In 2022, the Corporation sold its interests in Valparaiso Medical Development, LLC; the gain was not material.

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Although estimates are considered to be fairly stated at the time the estimates are made, actual results could differ from those estimates.

Cash Equivalents and Restricted Cash

All investments that are not limited as to use with a maturity of three months or less at the time of acquisition are reflected as cash equivalents. Cash equivalents include checking accounts, money market accounts, corporate credit card accounts, cash on account with vendors, and petty cash. The carrying value of cash equivalents approximates fair value. Highly liquid debt instruments with original, short-term maturities of less than 90 days that are included as part of assets limited

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

as to use are excluded from cash equivalents as they are commingled with longer-term investments. Amounts included in restricted cash include cash held within investments and represent funds set aside within the investment portfolio based on management's policy or contractual arrangements.

Short-Term Investments

Short-term investments include cash reinvested on a daily basis, accrued interest on investments, and money expected to be used in less than a year. Also included in short-term investments are restricted and unrestricted investment donations that are in the process of being liquidated.

Assets Limited as to Use

Assets limited as to use include assets set aside by the Board of Directors (the Board) for future capital improvements and community health enhancement initiatives that the Board, at its discretion, may subsequently use for other purposes. In addition, assets limited as to use also include assets held by trustees under self-funded insurance agreements, investments externally designated under indenture or donor restrictions, and money expected to be used as part of BHS's community benefit.

Investments

The Corporation classifies its investments as trading. Under a trading classification, all unrestricted realized and unrealized gains and losses are included in revenue and gains in excess of (less than) expenses.

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value based on quoted market prices for those or similar investments. Dividend and interest income, realized gains and losses, and changes to fair values of investments are reported as nonoperating investment income on the consolidated statements of operations and changes in net assets. Nonoperating investment income is reported net of internal and external investment costs.

Notes to Consolidated Financial Statements (continued)
(Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Investments in alternative investments, primarily hedge fund of funds, that invest in marketable securities, commingled funds, and private equity funds are accounted for under the equity method and are based on the net asset value of the investments. The calculated net asset values are provided by the respective fund managers and are based on historical costs, appraisals, and other estimates that require varying degrees of judgment.

Management has utilized the best available information for reported values, which in some instances are valuations as of an interim date not more than 90 days before year-end. Because alternative investments are not readily marketable, their estimated value is subject to uncertainty and may differ from the value that would have been used had a ready market for such investments existed. Resulting differences could be material. The financial statements of the hedge funds, commingled funds, and private equity funds are audited annually. Equity earnings related to these alternative investments are included in nonoperating investment income. The Corporation's holding reflects net contributions to the hedge fund and an allocated share of realized and unrealized investment income and expense.

Inventories

Inventories are stated at the lower of cost (average cost method) or market.

Unamortized Bond Issuance Costs

Costs incurred in connection with the issuance of long-term debt are deferred and amortized over the term of the related financing, which approximates the effective interest method.

Fair Value of Financial Instruments

The Corporation's carrying amount for its financial instruments, which include cash and cash equivalents, short-term investments and assets limited as to use, accounts receivable, debt, and interest rate and basis swaps at December 31, 2023 and 2022, approximates fair value. The estimated fair value amounts have been determined by the Corporation using available market information and appropriate valuation methodologies.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Property and Equipment

Property and equipment are carried at cost, except for donated assets, which are recorded at fair value at the date of donation. Allowances for depreciation and amortization are computed primarily utilizing the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years. Depreciation expense for the years ended December 31, 2023 and 2022, was \$61,845 and \$61,974, respectively.

Lease Right of Use Assets and Liabilities

The Corporation records a lease right of use (ROU) asset (that is, an asset that represents the Corporation's right to use the leased asset for the lease term) for leases with a term greater than 12 months and that do not meet the criteria as a sales-type lease or a direct financing lease.

The Corporation records financing lease ROU assets at the value of principal payments, adding initial direct costs and prepaid lease payments, reduced by any lease incentives. Financing ROU assets are amortized using the straight-line method over the related lease term. Amortization of financing lease ROU assets is included on the accompanying consolidated statements of operations and changes in net assets in depreciation and amortization expenses.

Asset Impairment

The Corporation considers whether indicators of impairment are present and performs the necessary tests to determine whether the carrying value of an asset is appropriate. Impairment write-downs are recognized in operating expenses at the time the impairment is identified. There were no impairments of long-lived assets in 2023 or 2022.

Deferred Charges and Other Assets

Included in deferred charges and other assets are intangible assets, long-term portion of ROUs, goodwill, and investments in unconsolidated affiliates.

The acquisition of a business entity can result in the recording of intangible assets. Acquired definite-lived intangible assets (excluding goodwill) are amortized over the useful life of the assets. Goodwill is carried at acquisition value, less any impairment reductions.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

The carrying value of goodwill amounted to approximately \$12,038 at December 31, 2023 and 2022, and is included in deferred charges and other assets on the consolidated balance sheets. Goodwill is assessed for impairment on an annual basis at the reporting unit level. If the fair value of the reporting unit is less than the carrying value, an impairment loss equal to the difference between the implied fair value of the reporting unit goodwill and the carrying value of the reporting unit goodwill is recognized. There was no impairment of goodwill in 2023 or 2022.

The Corporation accounts for its investments in less than majority-owned and controlled affiliates using the equity method of accounting. Income from these investments is reflected in other revenue on the consolidated statements of operations and changes in net assets.

Endowment Investments

Income is received directly by BHF from BHF board-designated quasi-endowment investments and quasi-endowments with restriction and is included in investment income within both net assets with and without donor restrictions. EGH receives a portion of the income from investments in endowments directly as they are released from restriction. These endowment investments have perpetual existence.

Contributions

Unconditional pledges to give cash and other assets are reported at fair value at the date the pledge is received to the extent estimated to be collectible by the Corporation.

Net Assets Without Donor Restrictions

Net assets without donor restrictions are available for use at the discretion of the Board and/or management for general operating purposes.

Net Assets With Donor Restrictions

Net assets with donor restrictions consist of assets whose use is limited by donor-imposed, time, and/or purpose restrictions.

Notes to Consolidated Financial Statements (continued)
(Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

The Corporation reports pledges, gifts of cash, and other assets as revenue with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, the net assets are reclassified as net assets without donor restrictions and reported on the consolidated statements of operations and changes in net assets as net assets released from restrictions. Assets released from restrictions that are used for the purchase of property and equipment or capital purposes are reported on the consolidated statements of operations and changes in net assets as additions to net assets without restrictions. Resources restricted by donors for specific operating purposes are reported in revenue without restrictions, gains, and other support to the extent expended within the period.

Some net assets have been restricted by donors to be maintained by the Corporation in perpetuity. In accordance with the restriction, a majority of the investment income and investment gains or losses from these net assets are restricted by the donor for a specific purpose. A specified portion of income earned by the net assets is released from restrictions and used for operations each year and, therefore, is included on the consolidated statements of operations and changes in net assets as other revenue.

Patient Service Revenue and Patient Accounts Receivable

Patient service revenue and patient accounts receivable are reported at the amount that reflects the consideration to which BHS expects to be entitled in exchange for providing patient care. BHS has agreements with various third-party payors that provide for payments to BHS at amounts different from its established rates. Third parties include Medicare, Medicaid, managed health care plans, and other commercial plans. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. These amounts include estimated adjustments under certain reimbursement agreements with third-party payors, which are subject to audit by the applicable administering agency. These adjustments are accrued on an estimated basis and are adjusted in future periods as final settlements are determined (see Note 3). The Hospitals provide care to all patients regardless of their ability to pay. Charity care provided is excluded from patient service revenue (see Note 4).

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Performance Indicator

The consolidated statements of operations and changes in net assets include a performance indicator, revenue and gains in excess of (less than) expenses. Changes in net assets without restrictions, which are excluded from revenue and gains in excess of (less than) expenses, consistent with industry practice, include contributions of long-lived assets, including assets acquired using contributions, which, by donor restrictions, were to be used for the purpose of acquiring such assets.

Allocation of Costs

The Corporation's ability to exercise control over consolidated entities could result in the entities having a financial position or operating results that are significantly different from those that would have been obtained if the entities were autonomous. The manner of allocating certain shared and centralized costs, such as accounts payable processing, information technology support, and other Corporation-managed administration costs, is determined by the Corporation utilizing Internal Revenue Service transfer pricing guidance and is not audited. Alternate methods of accounting for these cost allocations may produce significantly different operating results for each of the consolidated entities.

Interest Rate and Basis Swaps

All interest rate and basis swaps are measured at fair value based on techniques consistent with the market approach. None of the swaps are designated as hedging instruments; therefore, the unrealized gains or losses on the fair value of the swaps are included in revenue and gains (less than) in excess of expenses on the consolidated statements of operations and changes in net assets.

Asset Retirement Obligations

The Corporation accounts for the fair value of legal obligations associated with long-lived asset retirements by recognizing an expense and accreting a liability over the life of the asset to cover potential legal obligations at the end of the asset's useful life. The asset retirement obligation primarily relates to future asbestos remediation related to buildings on MHSB's campus, as well as ground/soil remediation associated with the removal of underground fuel tanks. The carrying value of the obligation amounted to approximately \$5,560 and \$5,383 at December 31, 2023 and 2022, respectively, and is reflected in other liabilities on the consolidated balance sheets.

Notes to Consolidated Financial Statements (continued)
(Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Reclassifications

Certain prior year amounts have been reclassified for consistency with current year presentation.

New Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. (ASU) 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.* This ASU requires entities to report "expected" credit losses on financial instruments and other commitments to extend credit rather than the current "incurred loss" model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. This ASU was effective for BHS beginning January 1, 2023. BHS has adopted this ASU with no material impact to its consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, *Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting*. ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and applies only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. BHS adopted the standard as of January 1, 2023. The adoption of this ASU did not have a significant impact on BHS's consolidated financial statements or notes.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

3. Revenue and Accounts Receivable

Patient Service Revenue

Patient service revenue is reported at the amount that reflects the consideration to which the Corporation expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Corporation bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Corporation. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Corporation believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Corporation's hospitals receiving inpatient acute care services. The Corporation measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Corporation has elected to apply the optional exemption and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Corporation uses a portfolio approach to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes for inpatient revenue and outpatient revenue. Based on the historical collection trends and other analyses, the Corporation believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

3. Revenue and Accounts Receivable (continued)

The Corporation determines the transaction price, which involves significant estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to third-party payors, discounts provided to uninsured and underinsured patients in accordance with the Corporation's policy, and/or implicit price concessions based on the historical collection experience of patient accounts.

The Corporation determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Disproportionate Share Hospital (DSH) payments by the state of Indiana (the State), if eligible, are paid according to the fiscal year of the State, which ends on June 30 of each year, and are based on the cost of uncompensated care provided by the DSH providers during their respective fiscal year ended during the State's fiscal year. In 2016, MHSB qualified for the State DSH program for State fiscal years (SFYs) 2016 and 2017. In 2018, MHSB qualified for the State DSH program for SFYs 2018 and 2019. In 2021, MHSB qualified for the State DSH program for SFYs 2022 and 2023. MHSB recorded patient service revenue of \$16,998 and \$42,226 for the years ended

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

3. Revenue and Accounts Receivable (continued)

December 31, 2023 and 2022, respectively, related to the State DSH program. The amounts recorded for prior state fiscal years represent changes in estimates from prior period estimates. The following is a summary by SFY:

	 2023	2022
SFY 2024	\$ 7,223 \$	_
SFY 2023	5,914	8,531
SFY 2022	4,898	9,386
SFY 2021	(2,297)	5,361
SFY 2020	1,260	18,948
	\$ 16,998 \$	42,226

In April 2014, the Indiana Hospital Assessment Fee program (HAF) was approved by the Centers for Medicare & Medicaid Services retroactively for the period July 1, 2013 to June 30, 2017. The current state budget extended HAF through June 30, 2024. Under HAF, Indiana hospitals receive additional federal Medicaid funds for the State's health care system, administered by the Indiana Family and Social Services Administration. HAF includes both a payment to the Hospitals from the State (included in patient service revenue) and an assessment (included in supplies and other expenses) against the Hospitals, which is paid to the State the same year. BHS recognized HAF revenues and assessments as follows:

Year Recognized			
2	023	2022	Total
\$ 13	32,466	\$ -	\$ 132,466
(5	52,306)	_	(52,306)
	_	123,674	123,674
	2,623	(47,586)	(44,963)
	602	(171)	431
	_	619	619
\$ 8	33,385	\$ 76,536	\$ 159,921
	\$ 13 (5	\$ 132,466 (52,306) - 2,623	2023 2022 \$ 132,466 \$ - (52,306) - - 123,674 2,623 (47,586) 602 (171) - 619

HAF revenue is included in patient service revenue, and HAF assessments are included in supplies and other expenses on the consolidated statements of operations and changes in net assets.

Notes to Consolidated Financial Statements (continued)
(Dollars in Thousands)

3. Revenue and Accounts Receivable (continued)

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Corporation's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Corporation. In addition, the contracts the Corporation has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Corporation's historical settlement activity, including an assessment to ensure that it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, or investigations.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Corporation also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Corporation estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change.

Estimates for DSH, settlements with third-party payors, and other contractual adjustments can differ from actual reimbursement based on the results of subsequent reviews, government regulatory changes, and cost report audits. For the years ended December 31, 2023 and 2022,

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

3. Revenue and Accounts Receivable (continued)

patient service revenue has been increased by approximately \$12,499 and \$23,147, respectively, for changes in estimates of third-party payor settlements related to prior years. There were no other significant changes to the judgments used to determine the transaction price in prior periods.

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the payors and service lines that render services to patients. Patient service revenue recognized for the years ended December 31 from major payor sources is as follows:

Payor	2023			2022		
Anthem	\$	289,218	22%	\$	255,979	21%
Commercial		343,804	27		310,973	26
Medicare		406,173	31		354,840	29
Medicaid		228,288	18		274,865	23
Self-pay		22,521	2		8,727	1
Patient service revenue	\$	1,290,004	100%	\$	1,205,384	100%

The composition of patient care service revenue based on service lines the Corporation operates for the years ended December 31 is as follows:

Service Lines	2023	}	2022		
Hospitals	\$ 1,108,537	86%	\$ 1,041,354	86%	
Medical Group	166,838	13	150,665	13	
Other	14,629	1	13,365	1	
Patient service revenue	\$ 1,290,004	100%	\$ 1,205,384	100%	

2401-4414437 23

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

3. Revenue and Accounts Receivable (continued)

Credit is granted without collateral to patients, most of whom are local residents and are insured under third-party arrangements. The composition of patient accounts receivable for years ended December 31 by major payor sources is as follows:

Payor	2023	2022
Anthem	24%	22%
Commercial	40	36
Medicare	20	24
Medicaid	9	11
Self-pay	7	7
Patient service revenue	100%	100%

The Corporation has elected the practical expedient and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Corporation's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that services will be one year or less. However, the Corporation does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

The Corporation has applied the practical expedient and all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Corporation otherwise would have recognized is one year or less in duration.

Other Revenue

Other revenues consist of revenues associated with retail services, such as pharmacy and cafeteria, ancillary services and strategic initiatives with entities with less than majority ownership or noncontrolling interests (joint ventures) by the Corporation, health and fitness membership, and leased space rental agreements with third parties. Revenues associated with pharmacy services are estimated as prescriptions are filled and collected by patients. Retail sales are recorded at the time of service. Revenues associated with joint ventures are recognized on the equity method. Health and fitness revenue is recognized over the membership period and leased space rental revenue is recognized over the term of the lease.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

3. Revenue and Accounts Receivable (continued)

The composition of other revenue for the years ended December 31 is as follows:

Service Lines	2023		2022	
Retail service revenue	\$	25,397 \$	18,657	
Joint venture (loss) income		(1,133)	4,533	
Grant revenue*		6,433	32,502	
Health and fitness revenue		9,592	7,897	
Rental revenue		3,414	2,973	
Other revenue		28,567	22,057	
	\$	72,270 \$	88,619	

^{*} Grant revenue includes federal CARES Act and FEMA funding. CARES Act funding included for the years ended December 31, 2023 and 2022, was approximately \$205 and \$4,722, respectively. FEMA funding included for the 12 months ended December 31, 2023 and 2022, was approximately \$0 and \$21,036, respectively.

As of December 31, 2023 and 2022, the Corporation received \$205 and \$4,722, respectively, in grant payments from the U.S. Department of Health and Human Services from the Provider Relief Fund established under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which has been recognized as revenue and included in other operating revenue within the consolidated statements of operations and changes in net assets. Payments from the Provider Relief Fund are intended to cover patient care lost revenues and qualified expenses, net of other reimbursed sources, attributed to COVID-19 and are not required to be repaid provided the recipient attests to and complies with the terms and conditions of the grant funds. The recognition of this support falls under the grant accounting guidance of accounting principles generally accepted in the United States of America. This guidance requires all significant terms and conditions to have been met for recognition to occur. Management of the Corporation will continue to monitor compliance with the terms and conditions of the CARES Act grant funds and the impact of the pandemic on the Corporation's consolidated results of operations.

2401-4414437 25

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

3. Revenue and Accounts Receivable (continued)

As of December 31, 2022, the Corporation received \$21,036 of funding from the Federal Emergency Management Agency (FEMA) for the reimbursement of costs incurred in response to the COVID-19 pandemic, which included purchase of medical supplies and equipment, personal protective equipment, and overtime for medical staff providing clinical treatment of COVID-19 patients. FEMA reimbursement has been recorded as other revenue for the year ended December 31, 2022. No additional FEMA funds were received for the year ended December 31, 2023.

The CARES Act also permits employers to defer the employer portion of social security taxes. Employers were required to remit one half of the amount deferred by December 31, 2021, and the remaining half by December 31, 2022. The Corporation had deferred approximately \$14,284 of these taxes, of which \$6,816 was paid back in 2021 and \$7,468 was paid back in 2022.

4. Charity Care

Patients who meet the Corporation's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts determined to qualify as charity care are not reported as revenue.

Charity care represents unreimbursed costs for services rendered at a reduced fee, or no fee, due to the inability of the patient to pay for services. The amount of the charity care provided was approximately \$4,951 and \$3,746 for the years ended December 31, 2023 and 2022, respectively, at estimated cost. The Corporation utilized a cost to charge ratio methodology for the cost analysis. The only reimbursement for financial assistance care received by the Corporation is determined through a settlement process in the Hospitals' annual Medicare cost report filing. Financial assistance care reimbursement was approximately \$1,110 and \$518 for the years ended December 31, 2023 and 2022, respectively.

5. Retirement Plans

The Corporation maintains a defined contribution employee retirement and savings plan for all employees who have attained 21 years of age and have completed 12 months of continuous service. The Corporation's contributions are based on 100% of the employee's contributions, up to 4% of the employee's salary. Both employee and corporation contributions are subject to certain limitations. The benefit plan expense for the years ended December 31, 2023 and 2022, was approximately \$17,410 and \$15,289, respectively.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

6. Lease Obligations

The Corporation has leases for certain equipment. The lease term begins at the lease commencement date and is determined on that date based on the noncancelable term of the lease. The Corporation's financing lease terms are generally five years, ending at various dates from 2024 through 2026. The financing lease agreements have a fixed lease payment, with a purchase option at the end of the agreement.

The Corporation is using a discount rate of 0.46% for financing leases, which is the rate that is embedded in the lease agreements. The total financing lease payments that will be incurred over the life of the leases are \$5,036, of which \$5,022 is amortization and \$14 is interest.

The Corporation's operating lease was terminated in January 2022. The original lease term was 13 years, with the obligation ending in March 2026. The results of the lease termination were that \$3,150 was written off the operating ROU asset, \$3,189 was written off the operating lease liability, and \$39 was recognized as a gain on the lease termination.

The current portion of the financing ROU is included in other current assets and the long-term portion of the financing ROU is included in deferred charges and other assets. The current portion of the financing lease liability is included in other current liabilities and the long-term portion of the financing lease liability is included in other long-term liabilities. The table below sets forth a summary of the Corporation's ROU assets and lease liabilities at December 31:

	 2023	2022
Current portion of financing ROU asset Long-term portion of financing ROU asset	\$ 904 584	\$ 1,060 1,488
Total financing ROU assets	\$ 1,488	\$ 2,548
Current portion of financing lease liability Long-term portion of financing lease liability	\$ 933 594	\$ 1,077 1,527
Total financing lease liability	\$ 1,527	\$ 2,604

2401-4414437 27

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

6. Lease Obligations (continued)

At December 31, 2023, the minimum future lease payments under these leases are as follows:

	 <u> Fotal</u>
2024	\$ 872
2025 2026	443
2026	72
	\$ 1,387

Amortization expense for financing leases at December 31, 2023 and 2022, was \$1,060 and \$1,125, respectively, and is included in depreciation and amortization expense. Interest expense was not material for the years ended December 31, 2023 or 2022.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

7. Long-Term Debt

Long-term debt consists of the following at December 31:

	2023	2022
Tax-exempt bonds issued on behalf of BHS by the Indiana		_
Finance Authority:		
BHS Revenue Bonds, Series 2018, bearing interest at a variable		
rate of 4.89% at December 31, 2023, due in varying annual		
installments on December 15 of each year through 2043, with a		
mandatory tender date of December 15, 2028	\$ 29,000	\$ 30,000
BHS Revenue Refunding Bonds, Series 2017A, bearing interest at		
variable rates with a floating fixed interest rate swap of 4.97%		
at December 31, 2023, due in varying annual installments on		
August 15 of each year through 2033, with a mandatory tender date of May 1, 2028	35,745	36,020
BHS Revenue Refunding Bonds, Series 2017B, bearing interest at	33,743	30,020
a variable rate of 4.97% at December 31, 2023, due annually on		
May 1 of each year through 2033	33,200	34,525
BHS Revenue Bonds, Series 2013A, bearing interest at fixed rates	,	- ,-
of 5.00%, due in varying annual installments on August 15 of		
each year through 2023	_	6,380
BHS Revenue Bonds, Series 2021, bearing interest at a taxable		
fixed rate of 1.78% through May 2023, at which point the		
bonds did convert to tax exempt and became 2023 Bonds	_	60,685
BHS Revenue Bonds, Series 2023, bearing interest at a fixed rate		
of 1.46%, due in varying annual installments on August 15 of	50.54	
each year through 2034	59,515	_
Tax-exempt bonds issued on behalf of BHS by the Hospital Authority		
of St. Joseph County:		
BHS Revenue Bonds, Series 2022, bearing interest at a fixed rate of 2.17% until June 2037. This is due in varying annual		
installments on June 30 through 2052.	102,240	32,220
BHS Revenue Bonds, Series 2016, bearing interest at a fixed rate	102,240	32,220
of 3.92%, due in varying annual installments on August 15 of		
each year through 2046	42,790	44,525
BHS Revenue Bonds, Series 2013C, bearing interest at fixed rates	,	,e _e
between 3.75% and 5.00%, due in varying annual installments		
on August 15 of each year through 2044	46,130	46,130
Loan payable to Bank of America, dated October 22, 2021, monthly		
payments of principal and interest at a fixed rate of 1.94%. Due		
November 27, 2031, and secured by personal property	2,934	3,277
Loan payable to Bank of America, dated September 29, 2021, monthly		
payments of principal and interest at a fixed rate of 1.46%. Due	0.002	0.050
September 3, 2031, and secured by personal property	8,902	9,979

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

7. Long-Term Debt (continued)

Long-term debt consists of the following at December 31:

	2023	3	2022
Other obligations	\$	- \$	3,271
-	360),456	307,012
Bond issuance costs	(1	,449)	(1,231)
Unamortized premium		(400)	(419)
-	358	3,607	305,362
Less current portion	13	3,873	16,533
-	\$ 344	1,734 \$	288,829

In May 2022, the Hospital Authority of St. Joseph County, on behalf of BHS, issued revenue bonds Series 2022 (2022 Bonds) in the principal amount of \$150,000 to be drawn down in installments through June 2024, at which point it will be held in escrow until needed to fund capital projects. The interest rate for 2022 Bonds is a fixed rate of 2.17% due in annual installments through 2052. In 2023, the Corporation drew \$70,020 on the 2022 Bonds.

In September 2021, the Indiana Finance Authority, on behalf of BHS, issued revenue refunding bonds Series 2021 (2021 Bonds) in the principal amount of \$61,730. The 2021 Bonds were taxable bonds that converted to tax-exempt bonds in May 2023 (2023 Bonds). The 2021 Bonds were private placement bonds, bearing interest at a fixed monthly interest rate. The proceeds from the 2021 Bonds were utilized to refund a portion of the BHS Revenue Bonds, Series 2013A.

In June 2023, the Indiana Finance Authority, on behalf of BHS, issued revenue refunding bonds Series 2023 (2023 Bonds) in the principal amount of \$60,685. The 2023 Bonds are tax-exempt bonds. The 2023 Bonds are private placement bonds, bearing interest at a fixed monthly interest rate. The proceeds from the 2023 Bonds were utilized to refund the BHS Revenue Bonds, Series 2021.

In December 2018, the Indiana Finance Authority, on behalf of BHS, issued revenue bonds Series 2018 (2018 Bonds) in the principal amount of \$35,000. The 2018 Bonds are private placement bonds, bearing interest at a variable monthly interest rate. Proceeds from the 2018 Bonds were utilized to fund existing and future capital projects.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

7. Long-Term Debt (continued)

In September 2017, the Indiana Finance Authority, on behalf of BHS, issued revenue refunding bonds Series 2017A (2017A Bonds) in the principal amount of \$37,240. The 2017A Bonds are private placement bonds, bearing interest at a variable monthly interest rate. The proceeds from 2017A Bonds were utilized to refund the MHSB Revenue Bonds, Series 2008A. In May 2023, the variable interest rate was refinanced for a five-year term.

In September 2017, the Indiana Finance Authority, on behalf of BHS, issued revenue refunding bonds Series 2017B (2017B Bonds) in the principal amount of \$40,210. The 2017B Bonds are private placement bonds, bearing interest at a variable monthly interest rate. The proceeds from 2017B Bonds were utilized to refund the EGH Revenue Bonds, Series 2008. In May 2023, the variable interest rate was refinanced for a five-year term.

In August 2016, the Hospital Authority of St. Joseph County issued Hospital Revenue Bonds, Series 2016 (Series 2016 Bonds), on behalf of the Obligated Group. The Series 2016 Bonds are \$50,000 private placement bonds due in varying installments through 2046. In 2023 the Corporation refinanced the Series 2016 Bonds, for a ten-year term, which now bear interest at a fixed rate of 3.92%. Proceeds from the Series 2016 Bonds were utilized to fund existing and future capital projects.

In May 2013, the Indiana Finance Authority, on behalf of BHS, issued revenue refunding bonds Series 2013A (2013A Bonds) in the principal amount of \$116,705. The interest rate for 2013A is a fixed rate varying between 2.00% and 5.00%. The proceeds from 2013A Bonds were utilized to refund the MHSB Revenue Bonds, Series 2008B; MHSB Revenue Bonds, Series 1998A; and EGH Revenue Bonds, Series 1998. In September 2021, a portion of the 2013A Bonds was refunded; the remaining amount of the 2013A Bonds was paid in full in August 2023.

In May 2013, the Hospital Authority of St. Joseph County, on behalf of BHS, issued revenue bonds Series 2013C (2013C Bonds) in the principal amount of \$46,130. The interest rate for 2013C Bonds is a fixed rate varying between 3.75% and 5.00%. The proceeds from 2013C Bonds were utilized to refund the MHSB Revenue Bonds, Series 2007. The remaining proceeds are set aside in externally designated investments for future projects.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

7. Long-Term Debt (continued)

The Corporation is the Obligated Group Agent for the Obligated Group under the Master Trust Indentures. The Obligated Group includes the Corporation, MHSB, EGH, and BMG. BHF and BHV constitute designated affiliates under the terms of the Master Trust Indentures. The bonds are secured by pledged revenues of the Obligated Group and contain various covenants, including achievement of specified financial ratios and limitations on additional debt.

The loan agreements require maintenance of certain debt service coverage ratios, limit additional borrowings, and require compliance with various other restrictive covenants. The Corporation was in compliance with all covenants during 2023 and 2022.

The Corporation entered into a loan with Bank of America, dated October 22, 2021, to refinance TRH's debt with the United States Department of Agriculture (USDA) and Horizon Bank. The loan with Bank of America bears interest at a fixed rate of 1.94%. TRH's outstanding loan with Bank of America is secured by personal property of EGH.

TRH entered into a loan with the City of Three Rivers, State of Michigan, dated February 14, 2020, in the amount of \$131. The loan with the City of Three Rivers bears interest at a fixed rate of 3.00%. TRH's outstanding loan with the City of Three Rivers is secured by an agreement between TRH and the City of Three Rivers and a mortgage. The loan was paid in full in March 2022.

The Corporation entered into a loan with Bank of America, dated September 29, 2021, to refinance CHB's debt with Lake City Bank and the USDA. The loan with Bank of America bears interest at a fixed rate of 1.46%. CHB's outstanding loan with Bank of America is secured by personal property of MHSB, EGH, and CHB.

Interest capitalized for the years ended December 31, 2023 and 2022, was approximately \$1,836 and \$742, respectively.

Maturities of long-term debt and other obligations for each of the next five years are as follows:

2024	\$ 13,873
2025	15,126
2026	16,774
2027	17,133
2028	17,082

Notes to Consolidated Financial Statements (continued)
(Dollars in Thousands)

8. Line of Credit

The Corporation had a \$2,000 revolving line of credit with 1st Source Bank. The line of credit was terminated on May 31, 2023. Of the \$2,000 revolving line of credit, \$50 was segregated for the beneficiary of a self-insurance trust. Conversely, \$1,950 was available to be drawn upon. No draws were taken by the Corporation in either 2023 or 2022. The interest rate on the line of credit was the prime rate minus 0.50%. No amounts were outstanding on the line of credit as of December 31, 2023 or 2022.

9. Interest Rate and Basis Swaps

MHSB has various derivative instruments related to long-term debt obligations to manage the exposure on interest rates and MHSB's interest expense. Through the use of derivative financial instruments, MHSB is exposed to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contracts. When the fair value of the derivative contract is positive, the counterparty owes MHSB, which creates credit risk to MHSB. When the fair value of the derivative contract is negative, MHSB owes the counterparty, and there is no credit risk to MHSB at that point in time. MHSB minimizes the credit risk in derivative instruments by entering into transactions that require the counterparty to post collateral for the benefit of the fair value of the derivative contract. Market risk is the adverse effect on the value of the financial instrument that results from a change in interest rates. The management of market risk associated with interest rate changes is defined in MHSB's Swap Management Policy (the Policy). The Policy includes continuous monitoring of market conditions, emergent opportunities, and risks. Swap management is meant to be long term in nature, and any modifications to the program are reviewed for the long-term costs and benefits.

Management also mitigates risk through periodic reviews of its derivative position in the context of its total blended cost of capital.

The derivative instruments require adherence to collateral posting thresholds. In May 2023, Deutsche Bank was replaced as counterparty with The Bank of New York Mellon. For the 12 months ended December 31, 2023, the mark-to-market valuation on the swap portfolio was below the required collateral posting threshold of \$30,000 with Morgan Stanley, \$25,000 with Wells Fargo, and \$25,000 with The Bank of New York Mellon. For the 12 months ended December 31, 2022, the mark-to-market valuation on the swap portfolio was below the required collateral posting threshold of \$30,000 with Morgan Stanley, \$25,000 with Wells Fargo, and \$25,000 with Deutsche Bank.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

9. Interest Rate and Basis Swaps (continued)

The following is a summary of the outstanding fixed payor rate swaps as of December 31, 2023:

Origination Date	Notional Amounts	MHSB Receives	MHSB Pays	Maturity Date
March 2006	\$ 35,745	61.90% of (SOFR plus 0.11448%) plus 0.31%	3.5150%	August 2033
March 2003	5,900	65.00% of (SOFR plus 0.11448%) plus 0.45%	3.8100%	August 2034

The following is a summary of the outstanding fixed payor rate swaps as of December 31, 2022:

Origination Date	Notional Amounts	MHSB Receives	MHSB Pays	Maturity Date
March 2006	\$ 36,020	61.90% of 30-day LIBOR plus 0.31%	3.5150%	August 2033
March 2003	6,200	65.00% of 30-day LIBOR plus 0.45%	3.8100	August 2034

The following is a summary of the outstanding basis rate swaps as of December 31, 2023:

Origination Date	Notional Amounts	MHSB Receives	MHSB Pays	Maturity Date
January 2023	\$ 42,000	74.600% of (SOFR plus 0.11448%)	SIFMA tax-exempt index + 0.0715%	January 2041
July 2009	63,000	74.600% of (SOFR plus 0.11448%)	SIFMA tax-exempt index + 0.1700%	January 2041

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

9. Interest Rate and Basis Swaps (continued)

The following is a summary of the outstanding basis rate swaps as of December 31, 2022:

Origination Date	Notional MHSB Amounts Receives		MHSB Pays	Maturity Date
July 2010	\$ 42,000	74.600% of 1M LIBOR	SIFMA tax-exempt index + 0.0715%	January 2041
July 2009	63,000	74.600% of 1M LIBOR	SIFMA tax-exempt index + 0.1700%	January 2041

Net interest paid or received under the above swap agreements is included in interest expense. The net differential for MHSB as a result of the swap agreements amounted to payments of approximately \$486 and \$797 for the years ended December 31, 2023 and 2022, respectively, which is reflected as an increase in interest expense. The swap agreements do not qualify for hedge accounting; therefore, the change in the fair value of the swap agreements is recorded as an unrealized nonoperating gain of approximately \$4,953 and \$5,853 for the years ended December 31, 2023 and 2022, respectively.

The fair value of derivative instruments at December 31 is as follows:

	Consolidated Balance Sheet Location	2	2023	2022
Derivatives not designated as hedging instruments	Interest rate and basis swaps	\$	(6,078) \$	(11,031)
	•	\$	(6,078) \$	(11,031)

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

10. Liquidity and Availability of Resources

As of December 31, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt, and capital expenditures not financed with debt, were as follows:

		2023	2022
Cash and cash equivalents	\$	115,964 \$	70,805
Short-term investments	·	84,949	32,935
Internally designated investments*		832,892	800,871
Restricted cash		6,778	5,708
Externally designated investments – insurance trust		2,884	2,760
Board-designated endowment		31,624	29,406
Endowment investments		11,220	10,152
Total financial assets		1,086,311	952,637
Less amounts unavailable for general expenditure due to:			
Restricted bond funds		(58,395)	(15,929)
Restricted by donors with purpose restrictions		(18,854)	(16,767)
Restricted by donors in perpetuity		(400)	(400)
Restricted for insurance trust		(2,884)	(2,760)
Board-designated endowment		(31,624)	(29,406)
Add liquidity resources:			
Unused line of credit		_	1,950
Total financial assets available for general expenditure			,
within one year	\$	974,154 \$	889,325

^{*} Internally designated investments include \$123,826 and \$121,075 of private equity funds at December 31, 2023 and 2022, respectively. These private equity funds have limited redemption opportunities with the general partner or in the secondary market.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

10. Liquidity and Availability of Resources (continued)

BHS has various investments to maintain and strengthen its financial wellbeing and liquidity. The management of investments is defined by the Corporation's investment policy and is under the direction of an investment committee consisting of external advisors and BHS employees with the knowledge and understanding to undertake the monitoring of market conditions, emergent opportunities, and risks to help maximize the financial strength of the investments while considering the liquidity needs of BHS.

11. Investments

Total investment return for the years ended December 31 is summarized as follows:

2023	2022
\$ 42,683 \$	(90,175)
30,526	19,190
(24)	(22,240)
\$ 73,185 \$	(93,225)
\$ 70,870 \$	(92,938)
1,074	(1,509)
 1,241	1,222
\$ 73,185 \$	(93,225)
\$	\$ 42,683 \$ 30,526 (24) \$ 73,185 \$ \$ \$ 70,870 \$ \$ 1,074 1,241

The Corporation's investments are exposed to various kinds and levels of risk. Equity mutual funds expose the Corporation to market risk, performance risk, and liquidity risk. Market risk is the risk associated with major movements of the equity markets. Performance risk is the risk associated with a corporation's operating performance. Fixed-income securities expose the Corporation to interest rate risk, credit risk, and liquidity risk. As interest rates change, the value of many fixed-income securities is affected, including those with fixed interest rates. Credit risk is the risk that the obligor of the security will not fulfill its obligations. Liquidity risk is affected by the willingness of market participants to buy and sell given securities. Liquidity risk tends to be higher for equities related to small capitalization companies. Due to the volatility of the capital markets, there is a reasonable possibility of changes in fair value, resulting in additional gains and losses in the near term.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

11. Investments (continued)

Alternative investments have similar risks as income and equity securities, although there may be additional risks. These investments consist principally of noncontrolling interests in limited liability partnerships (LLPs) and limited liability companies (LLCs). Because these funds are invested through LLCs and LLPs, the underlying net asset value of the investments is based on valuations provided by the managers. Nearly all of the hedge fund manager valuations are independently priced or verified by third-party administrators. Certain hedge fund investments also have restrictions on the timing of withdrawals, up to one year from December 31, 2023, which may reduce liquidity. Some private equity and real asset funds have limited redemption opportunities with the general partner or in the secondary market.

12. Fair Value of Financial Instruments

The carrying values of cash and cash equivalents, accounts receivable, deferred compensation investments, and accounts payable and accrued expenses are reasonable estimates of their fair values due to the short-term nature of these financial instruments.

Accounting Standards Codification (ASC) 820-10-50-2, *Fair Value Measurement – Overall – Disclosure*, establishes a three-level valuation hierarchy. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or a liability as of the measurement date. The three levels are defined as follows:

- Level 1 Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 Inputs to the valuation methodology include quoted prices for similar assets or liabilities in an active market and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instruments.
- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

12. Fair Value of Financial Instruments (continued)

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following tables present the financial instruments carried as of December 31, by caption, on the consolidated balance sheets by the valuation hierarchy defined above for those instruments carried at fair value, as well as the alternative investments that are reported on the equity method of accounting.

			20)23		
					Assets at	
				Fair	Net Asset	Carrying
	Level 1	Level 2	Level 3	Value	Value	Value
Assets						
Short-term investments ^(a)	\$ 84,949	\$ -	\$ -	\$ 84,949	\$ -	\$ 84,949
Internally designated						
investments:						
Blended fund	309,081	_	_	309,081	_	309,081
Total mutual funds	309,081	_	_	309,081	_	309,081
Common stock ^(a)	20,401	_	_	20,401	_	20,401
Alternatives:						
Hedge funds	_	_	_	_	54,301	54,301
Emerging markets	_	_	_	_	52,129	52,129
Private debt	_	_	_	_	18,125	18,125
Private equity	_	_	_	_	204,270	204,270
Real estate investment trust	_	_	_	_	65,271	65,271
Commingled funds	_	_	_	_	57,961	57,961
Other	_	_	_	_	_	_
Long/short equity	_	_	_	_	5,983	5,983
Relative value	_	_	_	_	29,796	29,796
Tactical trading	_	_	_	_	15,574	15,574
Total alternatives	_	_	_	_	503,410	503,410
Total internally designated	·					
investments	329,482	_	_	329,482	503,410	832,892

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

12. Fair Value of Financial Instruments (continued)

	2023							
					Assets at			
				Fair	Net Asset	Carrying		
	Level 1	Level 2	Level 3	Value	Value	Value		
Assets (continued)								
Restricted cash ^(a)	\$ 6,778	\$ -	\$ -	\$ 6,778	\$ -	\$ 6,778		
Externally designated								
investment – insurance trust:								
Fixed income ^(a)	2,884	_	_	2,884	_	2,884		
Board-designated endowment:								
Mutual funds: (a)								
Equities	1,545	_	_	1,545	_	1,545		
Blended fund	15,872	_	_	15,872	_	15,872		
Fixed income ^{(a), (b)}	427	48	_	475	_	475		
Equities ^(a)	5	_	_	5	_	5		
Alternatives		_	_	_	13,727	13,727		
Total board-designated								
endowment	17,849	48	_	17,897	13,727	31,624		
Endowment:								
Mutual funds: (a)								
Blended fund	6,016	_	_	6,016	_	6,016		
Equities ^(a)	2	_	_	2	_	2		
Alternatives		_			5,202	5,202		
Total endowment	6,018	_	_	6,018	5,202	11,220		
Total	<u>\$ 447,960</u>	\$ 48	\$ -	\$ 448,008	\$ 522,339	\$ 970,347		
Liabilities								
Swaps ^(c)	<u>\$</u> –	\$ -	\$ (6,078)			\$ (6,078)		
Total	\$ -	<u>\$</u> –	\$ (6,078)	\$ (6,078)	\$ -	\$ (6,078)		

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

12. Fair Value of Financial Instruments (continued)

			203	22		
				Eoir	Assets at	Commina
	Level 1	Level 2	Level 3	Fair Value	Net Asset Value	Carrying Value
Assets						
Short-term investments ^(a)	\$ 32,935	\$ -	\$ -	\$ 32,935	\$ -	\$ 32,935
Internally designated						
investments:						
Blended fund	238,944	_	_	238,944	_	238,944
Total mutual funds	238,944	_	_	238,944	_	238,944
Common stock ^(a)	18,323	_	_	18,323	_	18,323
Alternatives:						
Hedge funds	_	_	_	_	70,130	70,130
Emerging markets	_	_	_	_	58,740	58,740
Private debt	_	_	_	_	907	907
Private equity	_	_	_	_	186,316	186,316
Real estate investment trust	_	_	_	_	73,807	73,807
Commingled funds	_	_	_	_	61,743	61,743
Other	_	_	_	_	16	16
Long/short equity	_	_	_	_	19,746	19,746
Relative value	_	_	_	_	47,826	47,826
Tactical trading		_	_	_	24,373	24,373
Total alternatives	_	_	_	_	543,604	543,604
Total internally designated						
investments	257,267	_	_	257,267	543,604	800,871

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

12. Fair Value of Financial Instruments (continued)

	2022							
	Level 1	Level 2	Level 3	Fair Value	Assets at Net Asset Value	Carrying Value		
Assets (continued)								
Restricted cash ^(a)	\$ 5,708	\$ -	\$ -	\$ 5,708	\$ -	\$ 5,708		
Externally designated								
investment – insurance trust:								
Fixed income ^(a)	2,760	_	_	2,760	_	2,760		
Board-designated endowment:								
Mutual funds: ^(a)								
Equities	1,361	_	_	1,361	_	1,361		
Blended fund	14,096	_	_	14,096	_	14,096		
Fixed income ^{(a), (b)}	418	46	_	464	_	464		
Equities ^(a)	2	_	_	2	_	2		
Alternatives		_	_	_	13,483	13,483		
Total board-designated								
endowment	15,877	46	_	15,923	13,483	29,406		
Endowment:								
Mutual funds: (a)								
Blended fund	5,188	_	_	5,188	_	5,188		
Equities ^(a)	1	_	_	1	_	1		
Alternatives		_	_	_	4,963	4,963		
Total endowment	5,189	_	_	5,189	4,963	10,152		
Total	\$ 319,736	\$ 46	\$ -	\$ 319,782	\$ 562,050	\$ 881,832		
Liabilities								
Swaps ^(c)	\$ -	\$ -	\$ (11,031)	\$ (11,031)	\$ -	\$ (11,031)		
Total	\$ -	\$ -	\$ (11,031)	\$ (11,031)	\$ -	\$ (11,031)		

^(a) Pricing for mutual funds, short-term investments, equities, and government obligations is based on the open market and is valued on a daily basis.

⁽b) Pricing is based on the fair value of the securities and is valued on a monthly basis. Information used to value this account is provided by International Data Corp. (IDC). In the event that a security is not actively traded in the open market, the characteristics are matched to a comparable issue from the IDC data to appropriately value the holding.

⁽c) Pricing is based on discounted cash flows to reflect a credit spread adjustment in order to reflect "nonperformance" risk. The credit spread adjustment is derived from how other comparable entities' bonds price and trade in the market. As the credit spread adjustment is a significant component of the swap valuation and is an unobservable input, the swaps have been classified as Level 3.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

12. Fair Value of Financial Instruments (continued)

The following table sets forth a summary of changes in the fair value of the Corporation's Level 3 swaps for the years ended December 31:

	 2023	2022
Balance, beginning of year	\$ (11,031) \$	(16,884)
Unrealized gains, net	4,953	5,853
Balance, end of year	\$ (6,078) \$	(11,031)

For the year ended December 31, 2023, the Corporation recorded approximately \$4,953 in nonoperating gains, which primarily relates to gains of \$5,358 due to the change in the swaps' value and losses of \$405 to reflect the fair value of the uncollateralized portion of the swap balance. For the year ended December 31, 2022, the Corporation recorded approximately \$5,853 in nonoperating losses, which primarily relates to gains of \$5,593 due to the change in the swaps' value and gains of \$260 to reflect the fair value of the uncollateralized portion of the swap balance.

13. Functional Expenses

The Corporation provides general health care services to residents within its geographic location. Expenses related to this and general and administrative functions for the years ended December 31 are as follows:

		2023					2022					
		Health						Health				
		Care	Adm	ninistrative	•			Care	Adı	ministrative		
		Services	F	unctions		Total		Services	I	unctions		Total
Salaries and wages	\$	559,629	\$	60,641	\$	620,270	\$	587,177	\$	52,808	\$	639,985
Employee benefits		118,817		21,510		140,327		107,552		15,322		122,874
Supplies and other		325,853		10,234		336,087		318,408		10,727		329,135
Professional fees and purchased services		91,325		63,963		155,288		104,745		43,258		148,003
Depreciation and amortization		54,999		8,183		63,182		53,018		10,327		63,345
Interest		7,291		470		7,761		6,663		204		6,867
Total	\$ 1	1,157,914	\$	165,001	\$	1,322,915	\$ 1	1,177,563	\$	132,646	\$	1,310,209

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

14. Commitments

The Corporation has total commitments to invest \$362,700 in certain hedge funds and alternative investments. During the years ended December 31, 2023 and 2022, the Corporation invested approximately \$25,684 and \$57,495, respectively. The Corporation had a remaining unfunded commitment of approximately \$110,076 at December 31, 2023.

The Corporation has entered into various capital projects, including related commitments to construction managers, architects, and other vendors for software implementation. The commitments under these agreements was approximately \$228,786 of which approximately \$26,658 was paid at December 31, 2023. The Corporation has made additional payments related to these projects subsequent to December 31, 2023, and through the date of this report of approximately \$7,265.

15. Professional Liability Insurance

The Corporation is involved in lawsuits and various governmental investigations, audits, reviews, and administrative proceedings arising in the ordinary course of business. Additionally, the Corporation may be subject to additional claims alleging professional liability for medical malpractice. The Corporation has a claims-made policy that covers all entities and has a \$25,000 deductible per claim. Historically, MHSB and EGH have obtained separate professional liability insurance coverage under claims-made policies. The claims-made policy covers all years other than years that were self-funded. MHSB was self-funded for its professional and general liability coverage for the period from December 1, 2003 to November 30, 2009. EGH was self-funded for its professional and general liability coverage for the period from March 1, 2010 to April 1, 2012. The Indiana Medical Malpractice Act has provided recovery of up to \$1,250, per occurrence, with the first \$250 covered by the respective entity, for claims prior to July 1, 2017. For the period from July 1, 2017 to June 30, 2019, the coverage limit was \$1,650, per occurrence, with the first \$400 covered by the respective entity. Effective July 1, 2019, the coverage limit was increased to \$1,800, per occurrence, with the first \$500 covered by the respective entity. MHSB maintains a trust fund for its self-insurance program, which it will continue to maintain until all claims have been settled. The fair value of the trust fund at December 31, 2023 and 2022, was approximately \$2,884 and \$2,760, respectively. The amount of malpractice and general liability claims, including a component for incurred but not reported claims, was approximately \$4,801 and \$4,832, gross of an insurance recoverable at December 31, 2023 and 2022, respectively, which is included in other liabilities. The interest rate used to discount these claims was 3% at December 31, 2023 and 2022. In addition, at December 31, 2023 and 2022, the Corporation recognized a recoverable insurance asset of approximately \$4,287, which is included in deferred charges and other assets.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

16. Income Taxes

The Corporation and its related affiliates, except for BHV, have been determined to qualify as exempt from federal income tax under Section 501(a) as organizations described in Section 501(c)(3) of the Code.

Most of the income received by the Corporation and its related affiliates, except for BHV, is exempt from taxation as the income is related to the mission of the organization. Accordingly, there is no material provision for income tax for these entities. However, some of the income received by exempt entities is subject to taxation as unrelated business income. The Corporation and its subsidiaries file federal and various state income tax returns in the United States.

ASC 740, *Income Taxes*, requires that realization of an uncertain income tax position be more likely than not (i.e., greater than 50% likelihood of receiving a benefit) before it is recognized in the consolidated financial statements as the amount most likely to be realized assuming a review by tax authorities having all relevant information and applying current conventions. This interpretation also clarifies the financial statement classification of tax-related penalties and interest and sets forth new disclosures regarding unrecognized tax benefits. No amount was recorded for the years ended December 31, 2023 or 2022.

17. Net Assets Without Donor Restrictions

Net assets without donor restrictions are composed of the following at December 31:

	2023	2022
Undesignated Board-designated endowment	\$ 1,705,847 31,624	\$ 1,591,458 29,406
_	\$ 1,737,471	\$ 1,620,864

Board-Designated Endowment – The Board has designated a portion of net assets without donor restrictions as a board-designated endowment for the purpose of funding BHF's operational expenses.

Notes to Consolidated Financial Statements (continued) (Dollars in Thousands)

18. Net Assets With Donor Restrictions

Net assets with donor restrictions are available for the following purposes at December 31:

	 2023	2022
Net assets currently available for:		
Children's services	\$ 3,233 \$	2,424
Education	3,629	3,003
Patient care	10,026	9,276
System priorities	1,326	1,423
Community impact	610	617
Quasi-endowments	430	424
	\$ 19,254 \$	17,167

The various purposes of the above donor-restricted amounts are as follows:

Children's services – Programs and services for pediatric patients throughout the Corporation

Education – Formal and continuing education

Patient care – Specific patient care services lines (i.e., cancer, cardiac, and trauma)

System priorities – Specific system initiatives as determined throughout the Corporation requiring formal approval and funding

Community impact – Initiatives that focus on preventive care and education throughout the community

Quasi-endowments – Designated to be held in perpetuity, income generated to be used for indigent care and/or area of greatest need

19. Subsequent Events

The Corporation evaluated events and transactions occurring subsequent to December 31, 2023 through March 8, 2024, the date of issuance of the accompanying consolidated financial statements. During this period, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements.

Supplementary Information



Ernst & Young LLP 155 North Wacker Drive Chicago, IL 60606-1787 Tel: +1 312 879 2000 Fax: +1 312 879 4000 ey.com

Report of Independent Auditors on Supplementary Information

The Board of Directors Beacon Health System, Inc. and Affiliated Corporations

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying details of consolidated balance sheets and details of consolidated statements of operations and changes in net assets are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Ernst + Young LLP

March 8, 2024

Details of Consolidated Balance Sheet

(In Thousands)

December 31, 2023

	Consolidate	d Eliminations	Memorial Hospital of South Bend, Inc.	Beacon Medical Group, Inc.	Beacon Health Foundation, Inc.	Beacon Health Ventures, Inc.	Elkhart General Hospital, Inc.	Beacon Health System, Inc.	Community Hospital of Bremen, Inc.	Three Rivers Health Systems, Inc.
Assets			,	1,	, , , , , , , , , , , , , , , , , , ,		<u> </u>			
Current assets:										
Cash and cash equivalents	\$ 115,9	64 \$ -	\$ 21,531	\$ 11,055	\$ 151	\$ 900	\$ 14,493	\$ 46,011	\$ 2,767	\$ 19,056
Short-term investments	84,9	49 –	58,395	_	1,261	_	_	25,293	_	_
Patient accounts receivable	232,0	93 (5,714)	134,963	26,046	_	306	62,386	1,645	4,406	8,055
Due from third-party payors	49,7	04 –	40,056	1,836	_	_	3,692	_	603	3,517
Other receivables	15,9	46 –	2,562	1,442	2	335	840	9,998	225	542
Other current assets	9	05 –	671	_	_	_	_	135	99	_
Inventories	36,3	15 –	20,100	_	_	147	11,540	3,160	337	1,031
Prepaid expenses	21,2	- 68	734	691	_	7	522	19,043	51	220
Due from affiliates		- (32,042)	_	20	_	_	_	32,022	_	_
Total current assets	557,1	44 (37,756)	279,012	41,090	1,414	1,695	93,473	137,307	8,488	32,421
Assets limited as to use:										
Internally designated investments	832,8	92 –	_	_	_	_	_	832,892	_	_
Restricted cash	6,7	78 –	-	_	6,778	_	_	_	_	_
Externally designated investments - insurance trust	2,8	84 –	2,853	21	_	10	_	_	_	_
Board-designated endowment	31,6	24 –	_	_	31,624	_	_	_	_	_
Endowment and temporarily restricted investments	11,2	20 –	-	_	2,799	_	8,421	_	_	_
	885,3	98 –	2,853	21	41,201	10	8,421	832,892	_	
Property and equipment:										
Land	65,7	36 –	27,003	5,796	_	_	4,974	20,759	779	6,425
Buildings and improvements	973,7	- 65	537,628	81,719	94	1,931	278,533	52,028	10,084	11,748
Furniture and equipment	548,7	10 –	259,502	33,758	164	2,161	141,455	99,087	4,983	7,600
Construction-in-progress	60,7	37 –	47,501	3,587	_	_	4,402	4,882	52	313
	1,648,9	48 –	871,634	124,860	258	4,092	429,364	176,756	15,898	26,086
Less allowances for depreciation and amortization	904,4	17 –	502,614	58,166	239	3,277	260,715	69,430	5,572	4,404
	744,5	31 –	369,020	66,694	19	815	168,649	107,326	10,326	21,682
Deferred charges and other assets	79,4	46 (12,367)	6,616	12,672	12	30,889	3,692	35,991	1,941	_
Interest in net assets of recipient organization		- (10,833)	10,833	_	_	_	_	_	_	_
Total assets	\$ 2,266,5	19 \$ (60,956)	\$ 668,334	\$ 120,477	\$ 42,646	\$ 33,409	\$ 274,235	\$ 1,113,516	\$ 20,755	\$ 54,103

48 2401-4414437

Details of Consolidated Balance Sheet (continued)

(In Thousands)

December 31, 2023

				Memorial	Beacon	Beacon	Beacon	Elkhart	Beacon	Community	Three Rivers
				Hospital of	Medical	Health	Health	General	Health	Hospital of	Health
	Consolida	ted	Eliminations	South Bend, Inc.	Group, Inc.	Foundation, Inc.	Ventures, Inc.	Hospital, Inc.	System, Inc.	Bremen, Inc.	Systems, Inc.
Liabilities and net assets											
Current liabilities:											
Accounts payable	\$ 64	,287	\$ -	\$ 20,472	\$ 17,560	\$ 17	\$ 54	\$ 11,928	\$ 10,745	\$ 1,072	\$ 2,439
Accrued salaries and benefits	59	,640	(5,714)	24,833	12,993	_	58	11,370	12,855	257	2,988
Accrued expenses	4	,327	-	1,984	17	_	_	1,549	539	52	186
Other current liabilities		933	_	694	_	_	_	_	140	99	_
Due to third-party payors	2	,121	_	19	_	_	_	98	_	27	1,977
Due to affiliates		_	(32,042)	33	_	_	32,009	_	_	_	_
Current maturities of long-term debt	13	,873	_	5,673	-	_	_	4,082	2,675	1,093	350
Total current liabilities	145	,181	(37,756)	53,708	30,570	17	32,121	29,027	26,954	2,600	7,940
Noncurrent liabilities:											
Long-term debt, less current maturities	344	,734	_	217,062	_	_	_	48,527	68,752	7,809	2,584
Other liabilities	13	,801	_	9,048	23	_	11	1,633	2,904	182	_
Interest rate and basis swaps	6	,078	_	6,078	_	_	_	_	_	_	_
	364	,613	_	232,188	23	_	11	50,160	71,656	7,991	2,584
Total liabilities	509	,794	(37,756)	285,896	30,593	17	32,132	79,187	98,610	10,591	10,524
Net assets:											
Without donor restrictions	1,737	,471	(12,367)	371,605	89,884	31,796	1,277	186,627	1,014,906	10,164	43,579
With donor restrictions	19	,254	(10,833)	10,833	_	10,833	_	8,421	_	_	_
Total net assets	1,756	,725	(23,200)	382,438	89,884	42,629	1,277	195,048	1,014,906	10,164	43,579
Total liabilities and net assets	\$ 2,266	,519	\$ (60,956)	\$ 668,334	\$ 120,477	\$ 42,646	\$ 33,409	\$ 274,235	\$ 1,113,516	\$ 20,755	\$ 54,103

Details of Consolidated Balance Sheet (In Thousands)

December 31, 2022

	Co	onsolidated	Eliminations	Memorial Hospital of South Bend, Inc.	Beacon Medical Group, Inc.	Beacon Health Foundation, Inc.	Beacon Health Ventures, Inc.	Elkhart General Hospital, Inc.	Beacon Health System, Inc.	Community Hospital of Bremen, Inc.	Three Rivers Health Systems, Inc.
Assets			2	South Bena, The	oroup, mei	1 oundation, Inc.	, circuitos, inci	mospital, mei	sjotem, mei	Di cincii, inci	Systems, mer
Current assets:											
Cash and cash equivalents	\$	70,805	\$ -	\$ 21,953	\$ 3,968	\$ 245	\$ 2,003	\$ 11,227	\$ 19,267	\$ 2,113	\$ 10,029
Short-term investments		32,935	_	15,941	-	1,087	-	-	15,907	_	_
Patient accounts receivable		217,013	(4,022)	116,995	30,721	_	421	60,168	1,696	4,179	6,855
Due from third-party payors		34,409	_	31,164	354	_	_	777	_	_	2,114
Other receivables		37,603	12	10,156	3,363	105	344	5,431	17,359	166	667
Other current assets		1,060	_	735	_	_	_	-	226	99	_
Inventories		31,329	_	18,016	-	_	426	8,866	2,680	368	973
Prepaid expenses		22,502	_	963	925	_	1	517	19,679	20	397
Due from affiliates		_	(29,241)	_	18	_	_	-	29,223	_	_
Total current assets		447,656	(33,251)	215,923	39,349	1,437	3,195	86,986	106,037	6,945	21,035
Assets limited as to use:											
Internally designated investments		800,871	_	_	_	_	_	_	800,871	_	_
Restricted cash		5,708	_	_	_	5,708	_	_	_	_	_
Externally designated investments - insurance trust		2,760	_	2,730	20	_	10	_	_	_	_
Board-designated endowment		29,406	_	-	_	29,406	_	_	_	_	_
Endowment and temporarily restricted investments		10,152	_	_	_	2,338	_	7,814	_	_	_
		848,897	_	2,730	20	37,452	10	7,814	800,871	-	
Property and equipment:											
Land		68,572	_	26,982	5,675	_	_	4,553	24,355	779	6,228
Buildings and improvements		928,917	_	530,738	75,343	94	1,931	264,767	36,808	9,991	9,245
Furniture and equipment		523,444	_	255,015	34,069	164	2,134	136,471	86,375	4,681	4,535
Construction-in-progress		54,537	_	21,106	3,505	_	_	11,341	18,426	7	152
		1,575,470	-	833,841	118,592	258	4,065	417,132	165,964	15,458	20,160
Less allowances for depreciation and amortization		845,442	_	476,619	53,216	223	3,132	244,855	60,416	4,632	2,349
		730,028	-	357,222	65,376	35	933	172,277	105,548	10,826	17,811
Deferred charges and other assets		83,553	(12,367)	6,648	12,956	12	24,948	3,692	45,624	2,040	_
Interest in net assets of recipient organization		_	(9,353)	9,353	_	_	_	_	_	_	_
Total assets	\$	2,110,134	\$ (54,971)	\$ 591,876	\$ 117,701	\$ 38,936	\$ 29,086	\$ 270,769	\$ 1,058,080	\$ 19,811	\$ 38,846

Details of Consolidated Balance Sheet (continued) (In Thousands)

December 31, 2022

			Memorial	Beacon	Beacon	Beacon	Elkhart	Beacon	Community	Three Rivers
	Consolidated	Eliminations	Hospital of South Bend, Inc.	Medical Group, Inc.	Health Foundation, Inc.	Health Ventures, Inc.	General Hospital, Inc.	Health System, Inc.	Hospital of Bremen, Inc.	Health Systems, Inc.
Liabilities and net assets	Consondated	Elillillations	South Benu, Inc.	Group, Inc.	roundation, Inc.	ventures, inc.	mospital, mc.	System, Inc.	bremen, mc.	Systems, Inc.
Current liabilities:										
Accounts payable	\$ 73,905	\$ 12	\$ 25,332	\$ 18,776	\$ 9	\$ 318	\$ 15,898	\$ 10,052	\$ 787	\$ 2,721
Accrued salaries and benefits	54,230	(4,022)	24,489	11,840	_	_	11,107	8,787	_	2,029
Accrued expenses	4,966	_	1,122	_	_	_	795	2,422	52	575
Other current liabilities	1,076	_	748	_	-	_	_	229	99	_
Due to third-party payors	7,279	_	2,164	_	_	_	2,597	_	(44)	2,562
Due to affiliates	-	(29,241)	68	_	-	29,173	-	-	_	_
Current maturities of long-term debt	16,533	=	5,320	_	_	-	3,830	5,907	1,077	399
Total current liabilities	157,989	(33,251)	59,243	30,616	9	29,491	34,227	27,397	1,971	8,286
Noncurrent liabilities:										
Long-term debt, less current maturities	288,829	-	152,790	43	-	_	52,685	71,475	8,902	2,934
Other liabilities	14,254	_	9,576	23	_	11	1,652	2,711	281	_
Interest rate and basis swaps	11,031	=	11,031	_	_	-	=	_	_	<u> </u>
	314,114	=	173,397	66	-	11	54,337	74,186	9,183	2,934
Total liabilities	472,103	(33,251)	232,640	30,682	9	29,502	88,564	101,583	11,154	11,220
Net assets:										
Without donor restrictions	1,620,864	(12,367)	349,883	87,019	29,574	(416)	174,391	956,497	8,657	27,626
With donor restrictions	17,167	(9,353)	9,353	_	9,353		7,814	_	_	_
Total net assets	1,638,031	(21,720)	359,236	87,019	38,927	(416)	182,205	956,497	8,657	27,626
Total liabilities and net assets	\$ 2,110,134	\$ (54,971)	\$ 591,876	\$ 117,701	\$ 38,936	\$ 29,086	\$ 270,769	\$ 1,058,080	\$ 19,811	\$ 38,846

Details of Consolidated Statement of Operations and Changes in Net Assets (In Thousands)

Year Ended December 31, 2023

			Memorial Hospital of		Beacon Beacon Medical Health		Elkhart General	Beacon Health	Community Hospital of	Three Rivers Health	
	Consolidated	Eliminations	South Bend, Inc.	Group, Inc.	Foundation, Inc.	Health Ventures, Inc.	Hospital, Inc.	System, Inc.	Bremen, Inc.		
Unrestricted revenue, gains, and other support			,			<u> </u>	• /	• /			
Patient service revenue	\$ 1,290,004	\$ (7)	\$ 677,491	\$ 166,838	s –	\$ 3,295	\$ 338,972	\$ 11,341	\$ 26,252	\$ 65,822	
Other revenue	72,270	(12,467)	29,132	16,683	1,535	6,540	11,313	17,045	309	2,180	
Net assets released from restrictions											
used for operations	1,197	_	511	2	218	_	63	403	_	_	
	1,363,471	(12,474)	707,134	183,523	1,753	9,835	350,348	28,789	26,561	68,002	
Expenses											
Salaries and wages	620,270	_	197,344	213,760	687	3,239	101,423	66,405	10,291	27,121	
Employee benefits	140,327	(373)	48,156	34,338	291	913	24,464	23,595	2,719	6,224	
Supplies and other	336,087	(6,733)	167,263	34,524	696	2,623	101,583	17,668	4,795	13,668	
Management fees	_	_	81,336	21,320	212	890	42,556	(156,000)	3,235	6,451	
Professional fees and purchased services	155,288	(5,368)	40,407	13,693	126	334	18,144	70,702	4,480	12,770	
Depreciation and amortization	63,182	_	29,271	5,537	17	144	16,119	8,898	1,043	2,153	
Interest	7,761	_	5,610	_	_	_	1,483	470	137	61	
	1,322,915	(12,474)	569,387	323,172	2,029	8,143	305,772	31,738	26,700	68,448	
(Loss) income from operations	40,556	-	137,747	(139,649)	(276)	1,692	44,576	(2,949)	(139)	(446)	
Nonoperating (expenses) income											
Investment income (losses), net	70,870	_	918	130	2,336	1	191	66,910	50	334	
Unrealized gains on swap transactions, net	4,953	_	4,953	_	_	_	_	_	_	_	
Gain on lease termination	_	_	_	_	_	_	_	_	_	_	
Revenue and gains (less than) in excess of expenses	116,379	_	143,618	(139,519)	2,060	1,693	44,767	63,961	(89)	(112)	

Details of Consolidated Statement of Operations and Changes in Net Assets (continued) (In Thousands)

Year Ended December 31, 2023

				Memorial	Beacon	Beacon	Beacon	Elkhart	Beacon	Community	Three Rivers	
				Hospital of	Medical	Health	Health	General	Health	Hospital of	Health	
	Consoli	dated	Eliminations	South Bend, Inc.	Group, Inc.	Foundation, Inc.	Ventures, Inc.	Hospital, Inc.	System, Inc.	Bremen, Inc.	Systems, Inc.	
Net assets without donor restrictions												
Revenue and gains (less than) in excess of expenses	\$ 1	16,379	\$ -	\$ 143,618	\$ (139,519)	\$ 2,060	\$ 1,693	\$ 44,767	\$ 63,961	\$ (89)	\$ (112)	
Net assets released from restrictions used for												
capital purposes		228	_	128	_	_	_	50	_	50	_	
Net assets released from restriction by donor and other		_	_	_	_	_	_	_	_	_	_	
Other		_	_	(122,024)	142,384	161	_	(32,580)	(5,552)	1,546	16,065	
(Decrease) increase in net assets without donor restrictions	1	16,607	-	21,722	2,865	2,221	1,693	12,237	58,409	1,507	15,953	
Net assets with donor restrictions												
Purpose-restricted contributions		2,438	_	_	_	2,438	_	_	-	_	_	
Investment income (losses)		1,074	_	-	_	468	_	606	-	_	_	
Reclass of contribution restriction by donor		_	_	_	_	_	_	_	_	_	_	
Net assets released from restrictions												
used for operating and capital purposes		(1,425)	_	_	_	(1,425)	_	_	_	_	_	
Change in interest in recipient organization		-	(1,480)	1,480	_	-	_	_	_	_		
(Decrease) increase in net assets with donor restrictions		2,087	(1,480)	1,480	_	1,481	-	606	_	_		
Change in net assets	1	18,694	(1,480)	23,202	2,865	3,702	1,693	12,843	58,409	1,507	15,953	
Net assets at beginning of year	1,6	38,031	(21,720)	359,236	87,019	38,927	(416)	182,205	956,497	8,657	27,626	
Net assets at end of year	\$ 1,7	56,725	\$ (23,200)	\$ 382,438	\$ 89,884	\$ 42,629	\$ 1,277	\$ 195,048	\$ 1,014,906	\$ 10,164	\$ 43,579	

Details of Consolidated Statement of Operations and Changes in Net Assets (In Thousands)

Year Ended December 31, 2022

			Memorial	Beacon	Beacon	Beacon	Elkhart	Beacon	Community	Three Rivers	
			Hospital of	Medical	Health	Health	General	Health	Hospital of	Health	
	Consolidated	Eliminations	South Bend, Inc.	Group, Inc.	Foundation, Inc.	Ventures, Inc.	Hospital, Inc.	System, Inc.	Bremen, Inc.	Systems, Inc.	
Unrestricted revenue, gains, and other support											
Patient service revenue	\$ 1,205,384	\$ -	\$ 631,470	\$ 150,665	\$ -	\$ 3,263	\$ 323,007	\$ 10,102	\$ 22,648	\$ 64,229	
Other revenue	88,619	(19,422)	35,729	27,308	1,267	4,181	17,872	14,491	879	6,314	
Net assets released from restrictions											
used for operations	1,911	=	819	23	110	=	64	755	=	140	
	1,295,914	(19,422)	668,018	177,996	1,377	7,444	340,943	25,348	23,527	70,683	
Expenses											
Salaries and wages	639,985	_	221,364	194,926	663	3,093	122,600	58,107	10,699	28,533	
Employee benefits	122,874	(241)	44,900	29,466	127	758	22,552	17,146	2,246	5,920	
Supplies and other	329,135	(4,798)	159,150	34,693	331	2,386	99,054	16,626	4,394	17,299	
Management fees	-	_	67,623	18,485	192	699	36,017	(131,626)	2,620	5,990	
Professional fees and purchased services	148,003	(14,383)	42,946	13,242	133	260	28,507	58,283	4,449	14,566	
Depreciation and amortization	63,345	_	28,798	5,086	17	147	16,208	10,516	936	1,637	
Interest	6,867	=	5,257	-	=	=	1,174	204	153	79	
	1,310,209	(19,422)	570,038	295,898	1,463	7,343	326,112	29,256	25,497	74,024	
(Loss) income from operations	(14,295) –	97,980	(117,902)	(86)	101	14,831	(3,908)	(1,970)	(3,341)	
Nonoperating (expenses) income											
Investment (losses) income, net	(92,938) –	(115)	50	(4,181)	_	15	(88,846)	71	68	
Unrealized gains on swap transactions, net	5,853	-	5,853	_	-	_	-	-	_	_	
Gain on lease termination	39	-	_	_	-	39	-	-	_	_	
Revenue and gains (less than) in excess of expenses	(101,341) –	103,718	(117,852)	(4,267)	140	14,846	(92,754)	(1,899)	(3,273)	

Details of Consolidated Statement of Operations and Changes in Net Assets (continued) (In Thousands)

Year Ended December 31, 2022

				Memorial Hospital of	Beacon Medical	Beacon Health	Beacon Health	Elkhart General	Beacon Health	Community Hospital of	i	hree Rivers Health
	 onsolidated	Eliminations	8	South Bend, Inc.	Group, Inc.	Foundation, Inc.	Ventures, Inc.	Hospital, Inc.	System, Inc.	Bremen, In	c. Sy	stems, Inc.
Net assets without donor restrictions		_										
Revenue and gains (less than) in excess of expenses	\$ (101,341)	\$ -	\$	103,718	\$ (117,852)	\$ (4,267)	\$ 140	\$ 14,846	5 \$ (92,75	4) \$ (1,89	9) \$	(3,273)
Net assets released from restrictions used for												
capital purposes	1,499	-		1,390	90	-	-	16	5	_	3	_
Net assets released from restriction by donor and other	139	_		-	_	-	-	-	-	_	_	139
Other	_	_		(58,972)	117,321	83	-	15,926	(87,37	8) 8,91	3	4,107
(Decrease) increase in net assets without donor restrictions	(99,703)	-		46,136	(441)	(4,184)	140	30,788	(180,13	2) 7,01	7	973
Net assets with donor restrictions												
Purpose-restricted contributions	3,705	_		_	_	3,690	_	-	-	_	_	15
Investment (losses) income	(1,509)	_		_	_	(462)	-	(1,047	7)	_	_	_
Reclass of contribution restriction by donor	_	_		_	_		_	-	-	_	_	_
Net assets released from restrictions												
used for operating and capital purposes	(3,410)	_		_	_	(3,271)	-	-	-	_	_	(139)
Change in interest in recipient organization	_	42		(42)	_	_	_	-	-	_	_	_
(Decrease) increase in net assets with donor restrictions	(1,214)	42		(42)	-	(43)	_	(1,047	")	_	-	(124)
Change in net assets	(100,917)	42		46,094	(441)	(4,227)	140	29,741	(180,13	2) 7,01	7	849
Net assets at beginning of year	1,738,948	(21,762))	313,142	87,460	43,154	(556)				0	26,777
Net assets at end of year	\$ 1,638,031	\$ (21,720)		359,236	\$ 87,019	\$ 38,927		•	\$ 956,49	7 \$ 8,65	7 \$	27,626

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2024 Ernst & Young LLP. All Rights Reserved.

ey.com